A complete-case analysis of EPIC women with known FHBC (n = 138,257, 49% of the sample) showed positive homogenous associations between FHBC and tumor subtypes (HRER+ = 1.64, 95% CI = 1.49 to 1.81; HRER- = 1.50, 95% CI = 1.23 to 1.91; pheterogeneity = 0.57), suggesting that inclusion of this factor would increase the predictive power of the model, though not differentially across the hormonal receptor status of the tumors. Here, NR4A1 is linked to neoplasm.